VKTX logo

Viking Therapeutics Inc. (VKTX)

$28.99

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VKTX

Market cap

$3.38B

EPS

-4.67

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.678532

Price on VKTX

Previous close

$29.36

Today's open

$29.57

Day's range

$28.40 - $29.68

52 week range

$23.06 - $43.15

Profile about VKTX

CEO

Brian Lian

Employees

53

Headquarters

San Diego, CA

Exchange

NASDAQ Capital Market

Shares outstanding

116652937

Issue type

Common Stock

VKTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on VKTX

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

news source

Zacks Investment Research • Sep 18, 2026

news preview

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.

VK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phase 3 trials are successful. Tolerability and trial design adjustments are crucial for oral VK2735's success.

news source

The Motley Fool • Sep 17, 2026

news preview

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.

news source

Zacks Investment Research • Sep 17, 2026

news preview

Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.

news source

Zacks Investment Research • Sep 16, 2026

news preview

What's Going On With the Dip in Viking Therapeutics Stock?

Viking Therapeutics Inc. (NASDAQ:VKTX) shares are dropping Tuesday amid a broader risk-off session, even though the stock's longer-term uptrend and its sector's strength both remain intact.

news source

Benzinga • Sep 15, 2026

news preview

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

Viking Therapeutics NASDAQ: VKTX said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.

news source

MarketBeat • Sep 15, 2026

news preview

Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 14, 2026

news preview

Baron Global Opportunity Fund Q2 2026 Portfolio Activity

Baron Global Opportunity Fund (the Fund) gained 26.7% (Institutional Shares) during the second quarter, compared to the 14.9% gain for the MSCI ACWI Index (the Index). During the second quarter, we initiated five new positions: Alphabet, Samsung Electronics, Cerebras, DPC Holdings and Innio. We also took advantage of stock price volatility and significant inflows into the Fund to add to many existing positions including Shopify, Nu, NVIDIA, Amazon, GDS, ASML, TSMC, MercadoLibre, Tesla, ServiceTitan, and others.

news source

Seeking Alpha • Sep 14, 2026

news preview

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

news source

Zacks Investment Research • Sep 11, 2026

news preview

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high demand suggests there's room for additional players.

news source

The Motley Fool • Sep 10, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Viking Therapeutics Inc.

Open an M1 investment account to buy and sell Viking Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VKTX on M1